Paul L. Feldman, Chief Scientific Officer of Aktis Oncology, Inc., filed a Form 4 on November 19, 2026, disclosing the exercise of stock options and resulting changes in his beneficial ownership of common stock.

Key Highlights

  • Transaction date: November 18, 2026, involving 55,035 shares of common stock acquired via an option exercise (transaction code M).
  • Exercise price: The stock options carried a conversion/exercise price of $1.9022 per share.
  • Post-transaction common stock ownership: Feldman directly holds 199,603 shares of common stock following the reported transaction.
  • Options fully vested: According to the filing, "These options have vested in full," with an expiration date of April 14, 2031.
  • Remaining derivative securities: Feldman holds 10,678 stock options (right to buy) directly following the transaction, at a price of $0 for the derivative security itself.
  • Filing signatory: The form was signed by Kyle D. Kuvalanka as Attorney-in-Fact on November 19, 2026.

Feldman's Option Exercise and Beneficial Ownership at Aktis Oncology

According to the Form 4 filed with the SEC, Paul L. Feldman, who serves as Chief Scientific Officer of Aktis Oncology, Inc. (NASDAQ:AKTS), reported a single non-derivative transaction on November 18, 2026. The filing shows Feldman acquired 55,035 shares of common stock at a price of $1.9022 per share through an option exercise coded as "M" (exercise or conversion of derivative security). Following this transaction, the filing states his direct beneficial ownership of common stock stands at 199,603 shares.

In Table II of the filing, the corresponding derivative security, a stock option with the right to buy common stock at $1.9022, was disposed of via the same transaction code M on the same date. The filing notes in its explanation of responses that "These options have vested in full." The options carried an expiration date of April 14, 2031. The price of the derivative security itself is listed as $0. After the exercise, Feldman retains 10,678 stock options directly, according to the filing.

The form was filed on November 19, 2026, and signed by Kyle D. Kuvalanka as Attorney-in-Fact for Feldman. The filing indicates it was made by one reporting person, with Feldman's address listed as c/o Aktis Oncology, Inc., 17 Drydock Avenue, Suite 17-401, Boston, Massachusetts 02210.

What Was Disclosed

Paul L. Feldman, Chief Scientific Officer of Aktis Oncology, Inc., disclosed the exercise of 55,035 fully vested stock options at $1.9022 per share on November 18, 2026, bringing his direct common stock holdings to 199,603 shares, with 10,678 options remaining.